Scholarlink

<p>Complement-mediated metabolic disorders are considered important contributors to the pathogenesis of diabetic kidney disease (DKD). This study investigated the non-canonical roles of complement 5a receptor 2 (C5aR2) in metabolism and its underlying molecular mechanisms in DKD. In patients with DKD, we found that C5aR2 expression was upregulated in the tubulointerstitium and correlated with both disease severity and adverse renal outcomes. C5aR2 deficiency in diabetic mice exacerbated the DKD phenotype, including pronounced lipid accumulation, mitochondrial and endoplasmic reticulum (ER) dysfunction, and reduced phosphatidylserine (PS) levels in the kidney. Mechanistically, C5aR2 activated cellular Fos proto-oncogene (c-FOS) nuclear translocation, upregulated phosphatidylserine synthase (PSS) expression, and promoted the interaction between PSS and mitochondrial fusion protein 2 (MFN2), which facilitated mitochondria-associated ER membrane (MAM) formation and PS biosynthesis, improving mitochondrial and ER function. Treatment with the C5aR2-specific agonist P59 ameliorated the DKD phenotype, improved PS homeostasis and MAM formation, and thereby reversed lipid accumulation, ER stress, and mitochondrial dysfunction in <i>db/db</i> mice. Single-cell RNA sequencing (scRNA-seq) analysis revealed that P59 restored <i>Pss</i> expression in injured proximal tubular cells. These results highlight C5aR2 activation as a promising strategy for DKD treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Complement 5a receptor 2 attenuates diabetic kidney disease by promoting mitochondria-associated endoplasmic reticulum membrane formation mediated by PSS-MFN2 interaction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Yi-yang Zhao,
  • Yi-hui Wang,
  • Zi-han Li,
  • Dong-yuan Chang,
  • Lin Nie,
  • Ming-hui Zhao,
  • Sydney Chi Wai Tang,
  • Min Chen

摘要

Complement-mediated metabolic disorders are considered important contributors to the pathogenesis of diabetic kidney disease (DKD). This study investigated the non-canonical roles of complement 5a receptor 2 (C5aR2) in metabolism and its underlying molecular mechanisms in DKD. In patients with DKD, we found that C5aR2 expression was upregulated in the tubulointerstitium and correlated with both disease severity and adverse renal outcomes. C5aR2 deficiency in diabetic mice exacerbated the DKD phenotype, including pronounced lipid accumulation, mitochondrial and endoplasmic reticulum (ER) dysfunction, and reduced phosphatidylserine (PS) levels in the kidney. Mechanistically, C5aR2 activated cellular Fos proto-oncogene (c-FOS) nuclear translocation, upregulated phosphatidylserine synthase (PSS) expression, and promoted the interaction between PSS and mitochondrial fusion protein 2 (MFN2), which facilitated mitochondria-associated ER membrane (MAM) formation and PS biosynthesis, improving mitochondrial and ER function. Treatment with the C5aR2-specific agonist P59 ameliorated the DKD phenotype, improved PS homeostasis and MAM formation, and thereby reversed lipid accumulation, ER stress, and mitochondrial dysfunction in db/db mice. Single-cell RNA sequencing (scRNA-seq) analysis revealed that P59 restored Pss expression in injured proximal tubular cells. These results highlight C5aR2 activation as a promising strategy for DKD treatment.